Beijing, China

Chunyan Dong

USPTO Granted Patents = 10 

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2021-2024

where 'Filed Patents' based on already Granted Patents

10 patents (USPTO):

Title: Innovations by Chunyan Dong in Cancer Treatment

Introduction

Chunyan Dong is a prominent inventor based in Beijing, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of 10 patents, focusing primarily on innovative treatments for cancer. His work has the potential to impact the lives of many patients suffering from this devastating disease.

Latest Patents

Among his latest patents are groundbreaking developments in anti-PD-1 antibodies and anti-CD40 antibodies. The anti-PD-1 antibodies are designed to target the Programmed Cell Death Protein 1, offering new methods for treating cancer. Additionally, his work on anti-CD40 antibodies provides further advancements in cancer therapy, showcasing his commitment to improving treatment options.

Career Highlights

Chunyan Dong has worked with notable companies in the biopharmaceutical sector, including Eucure Biopharma Co., Ltd. and Biocytogen Pharmaceuticals Co., Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer research.

Collaborations

Chunyan has collaborated with talented individuals such as Chen Wang and Fang Yang, who have played essential roles in his research endeavors. Their combined expertise has fostered an environment of innovation and discovery.

Conclusion

Chunyan Dong's work in developing anti-PD-1 and anti-CD40 antibodies represents a significant advancement in cancer treatment. His contributions to the field of biopharmaceuticals highlight the importance of innovation in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…